IMUGENE CHART. TA only, page-12157

Agree there, IMU isn't trading like a biotech start-up because of the high MC valuation due to the market of all IMU's products which will allow high liquidity of the stock. This has allowed the stock to be listed on the ASX200 and does explain why I was very surprise with the level of activity on the charting thread for a biotech start-up. Given IMU's multiple IP attracting partnership from multiple big pharmacies during the clinical trial stage, there will always be buyer for the stock even with high amount of liquidity so traders can trade it I guess.

But let's wait until further positive/significant clinical trial results and then regulatory approval and see how chartist has predicted these multiple 50%+ rise from the chart. This will happen to IMU like all biotech start-up stock which will then allow me to show you this chart and why I say charting don't work on biotech start-up.